Celltrion Healthcare (Formerly Known As Celltrion)

1000 Marina Boulevard
Suite 200
Brisbane
California
94005
United States

Website: http://www.celltrionhealthcare.com/

About Celltrion Healthcare (Formerly Known As Celltrion)

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Jung Jini
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW CELLTRION:
Tweets by Celltrion

78 articles with Celltrion Healthcare (Formerly Known As Celltrion)

Hikma Reaches Licensing Agreement With Celltrion for Third Biosimilar Product in the Middle East and North Africa

12/19/2017

Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima, Remsima and Herzuma - in all its MENA markets.
Pfizer Release: One Year Maintenance and Switching Data in Patients with Crohn's Disease Support the Use of INFLECTRA (infliximab CT-P13) in IBD1

10/30/2017

Pfizer and Celltrion Healthcare jointly announced the secondary outcomes from the phase III trial of INFLECTRA in CD at the 25th United European Gastroenterology Week.
Celltrion Healthcare Taps Oracle Health Sciences Safety Solutions To Help Bring Cost-Effective Life-Saving And Biosimilar Drugs To Market

9/26/2017
Celltrion Healthcare: Biosimilar Trastuzumab Candidate, Ct-P6, Shown To Be Similar In Efficacy And Safety To Reference Trastuzumab In Breast Cancer Patients As Neoadjuvant And Adjuvant Treatment

9/11/2017
Celltrion Healthcare Showcases Data Supporting The Efficacy And Safety Of Truxima (CT-P10, Biosimilar Rituximab) In Advanced Follicular Lymphoma And Rheumatoid Arthritis

6/14/2017
Celltrion Healthcare Biosimilar Trastuzumab Candidate, CT-P6, Shown To Be Similar In Efficacy And Safety To The Reference Trastuzumab

6/5/2017
Celltrion Healthcare: Lancet Publishes Full Data-Set From Influential NOR-SWITCH Study

5/12/2017
Celltrion Healthcare Makes Move to Restrict Genentech’s Herceptin Patents in the U.S.

3/31/2017
Celltrion Healthcare Release: Truxima, The First Biosimilar Mab In Oncology, Granted EU Marketing Authorization

2/22/2017
Celltrion Healthcare Releases Positive Results From Pivotal Study In Crohn’s Disease

2/17/2017
Celltrion Healthcare Release: New Statement From European Crohn's And Colitis Organisation Supports Switching To Biosimilar From Reference Product In Inflammatory Bowel Disease

12/9/2016
Celltrion Healthcare Presents Positive Results For CT-P10, Biosimilar Rituximab Candidate, In Newly Diagnosed Advanced Stage Follicular Lymphoma

12/5/2016
Celltrion Healthcare Showcases Data Supporting Efficacy And Safety Of Both CT-P10 And CT-P13 Biosimilars

11/14/2016
Week In Review: Teva Pays $160 Million For US/Canada Rights To Celltrion Biosimilars

10/10/2016
Teva Pays $160 Million to Celltrion in Biosimilar Hook-Up

10/6/2016
Celltrion Announces Its Commitment To Develop Anti-Drug Antibody And Drug Concentration Assay To Enable Evidence-Based Decision-Making In anti-TNF Treatment

7/5/2016
FDAAdvisoryCommittee.com Approves Celltrion’s INFLECTRA, the First Cheaper Version of Johnson & Johnson Blockbuster Remicade

4/7/2016
FDA’s Arthritis Advisory Committee Recommends Approval Of Celltrion’s CT-P13, A Proposed Biosimilar Infliximab, For All Indications

2/10/2016
Johnson & Johnson Falls as FDA Staffers Back Celltrion's Remicade Biosimilar

2/9/2016
Celltrion, Inc. And Medidata Team Up To Transform Global Clinical Trials For Biosimilars

1/21/2016